At its investor day conference, Edwards Lifesciences Corp. prognosticated that an expanded indication in transcatheter aortic valve replacement and rapid growth in its newer mitral and tricuspid heart valve technologies will accelerate total company sales in 2026 and beyond.

Med-tech firms raised $23.65 billion in financings through November, an increase of 42% from $16.61 billion raised in the first 11 months of 2023. November’s value totaled $919.99 million, down from October’s $1.43 billion and $1.02 billion in September, but up from August's $3.67 billion.

Nua Surgical Ltd. secured €6.5 million ($6.9 million) in series A financing to support regulatory clearance in the U.S. and early commercialization of its Stericision C-section retractor. The device is a self-retaining surgical retractor designed to improve outcomes for mothers undergoing a caesarean section.

52 North Health Ltd. raised $6 million in financing to bring its oncology products to the market including the Neutrocheck, a point-of-care device and app which monitors cancer patients at home at risk of developing neutropenic sepsis.

The recent $73 million raised by Cradle NV in a series B financing round will allow the company to build out its operations and improve its artificial intelligence-powered protein engineering platform.